It is mentioned that genetic variability in AMP metabolism can be clinically relevant resulting from highly polymorphic character of CYP2D6. In idea, CYP2D6 very poor metabolizers could be predicted to demand lesser doses of AMP and/or be far more susceptible to adverse effects from routine scientific doses, even though CYP2D6 ultra-speedy metaboli